Volume 75, Issue 2, Pages (July 2012)

Slides:



Advertisements
Similar presentations
Sharen E. McKay, Wayne Yan, Jessica Nouws, Maximilian J
Advertisements

Volume 18, Issue 5, Pages (May 2010)
Sami Boudkkazi, Aline Brechet, Jochen Schwenk, Bernd Fakler  Neuron 
Volume 8, Issue 2, Pages (August 2003)
Mark E.J. Sheffield, Michael D. Adoff, Daniel A. Dombeck  Neuron 
Volume 66, Issue 6, Pages (June 2010)
Have You Heard? Viral-Mediated Gene Therapy Restores Hearing
Volume 25, Issue 5, Pages (March 2015)
Volume 71, Issue 5, Pages (September 2011)
Volume 25, Issue 2, Pages (February 2017)
VEGF Gene Delivery to Muscle
Volume 77, Issue 1, Pages (January 2013)
Volume 57, Issue 2, Pages (January 2008)
Felice A. Dunn, Luca Della Santina, Edward D. Parker, Rachel O.L. Wong 
Volume 71, Issue 2, Pages (July 2011)
Molecular Therapy - Methods & Clinical Development
Volume 24, Issue 6, Pages (March 2014)
Volume 77, Issue 1, Pages (January 2013)
Volume 58, Issue 3, Pages (May 2008)
Molecular Therapy - Methods & Clinical Development
Volume 14, Issue 1, Pages (July 2006)
Volume 4, Issue 6, Pages (December 2001)
Volume 25, Issue 5, Pages (March 2015)
Volume 73, Issue 3, Pages (February 2012)
Volume 31, Issue 6, Pages (September 2001)
RNA Interference Prevents Autosomal-Dominant Hearing Loss
EphA4-ADAM10 Interplay Patterns the Cochlear Sensory Epithelium through Local Disruption of Adherens Junctions  Jean Defourny, Christiane Peuckert, Klas.
Volume 2, Issue 3, Pages (March 2014)
HBL-1 Patterns Synaptic Remodeling in C. elegans
Volume 18, Issue 4, Pages (April 2010)
Molecular Therapy - Methods & Clinical Development
Volume 12, Issue 10, Pages (September 2015)
Volume 87, Issue 2, Pages (July 2015)
Volume 25, Issue 3, Pages (March 2017)
Volume 22, Issue 2, Pages (February 2012)
Homeostatic Plasticity Shapes Cell-Type-Specific Wiring in the Retina
T.M. Alie, P.J. Vrljicak, D.B. Myburgh, I.R. Gupta 
Mouse Otocyst Transuterine Gene Transfer Restores Hearing in Mice With Connexin 30 Deletion-associated Hearing Loss  Toru Miwa, Ryosei Minoda, Momoko.
Volume 86, Issue 6, Pages (June 2015)
Molecular Therapy - Methods & Clinical Development
Felice A. Dunn, Luca Della Santina, Edward D. Parker, Rachel O.L. Wong 
Donna M. Martin, Yehoash Raphael  Molecular Therapy 
Volume 84, Issue 5, Pages (December 2014)
Volume 49, Issue 2, Pages (January 2006)
Volume 62, Issue 2, Pages (April 2009)
Volume 10, Issue 11, Pages (March 2015)
Gordon X. Wang, Stephen J Smith, Philippe Mourrain  Neuron 
Overexpression of Fetuin-A Counteracts Ectopic Mineralization in a Mouse Model of Pseudoxanthoma Elasticum (Abcc6−/−)  Qiujie Jiang, Florian Dibra, Michael.
Volume 17, Issue 12, Pages (December 2009)
Figure 1 A B GCL NBL ED18.5 PND3 PND6 GCL
Volume 8, Issue 2, Pages (August 2003)
Volume 58, Issue 1, Pages (April 2008)
Volume 18, Issue 3, Pages (March 2010)
Figure 1 A B GCL NBL ED18.5 PND3 PND6 GCL
Volume 13, Issue 3, Pages (March 2006)
Tomokazu Sato, Mikhail G. Shapiro, Doris Y. Tsao  Neuron 
Volume 3, Issue 3, Pages (March 2001)
Sorting Nexin 27 Regulation of G Protein-Gated Inwardly Rectifying K+ Channels Attenuates In Vivo Cocaine Response  Michaelanne B. Munoz, Paul A. Slesinger 
Volume 14, Issue 3, Pages (September 2006)
Figure 1 A B GCL NBL ED18.5 PND3 PND6 GCL
Figure 1 A B GCL NBL ED18.5 PND3 PND6 GCL
Volume 26, Issue 5, Pages (May 2018)
Volume 24, Issue 1, Pages (January 2016)
Volume 15, Issue 5, Pages (May 2016)
Arc/Arg3.1 Mediates Homeostatic Synaptic Scaling of AMPA Receptors
Volume 18, Issue 5, Pages (May 2010)
Molecular Therapy - Methods & Clinical Development
Foxo3 is expressed in the adult mouse cochlea.
Volume 66, Issue 6, Pages (June 2010)
Molecular Therapy - Methods & Clinical Development
Presentation transcript:

Volume 75, Issue 2, Pages 283-293 (July 2012) Restoration of Hearing in the VGLUT3 Knockout Mouse Using Virally Mediated Gene Therapy  Omar Akil, Rebecca P. Seal, Kevin Burke, Chuansong Wang, Aurash Alemi, Matthew During, Robert H. Edwards, Lawrence R. Lustig  Neuron  Volume 75, Issue 2, Pages 283-293 (July 2012) DOI: 10.1016/j.neuron.2012.05.019 Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 1 AAV1-GFP Transduction in Mice Organ of Corti (A) AAV1-GFP was used to assess viral delivery to the cochlea on organ of Corti surface preparations. AAV1 transfects a number of cell types including inner (IHC) and supporting cells (white arrows, left) in the organ of Corti. The VGLUT3 KO (V3KO, middle) documents IHC labeling of transfected cells only. In the WT mouse (right), VGLUT3 colabels IHCs (red) along AAV1-GFP-transfected cells (green). (B) VGLUT3 expression after AAV1-VGLUT3 delivery via the RWM, delivered at P10–P12, and stained with anti-myosin 7A antibody (green, used as a hair cell marker, left column) and anti-VGLUT3 antibody (red, middle column) and merged (right column). WT mice show IHCs labeled with both anti-Myo7A and VGLUT3 as expected (top row, right), whereas KO mice only show Myo7a expression (middle row, right). After AAV1-VGLUT3 delivery, the IHC is colabeled by both anti-Myo7a and anti-VGLUT3 antibodies (bottom row, right) (TC, tunnel of Corti; DC, Deiter's cells; OHC, outer hair cells; IHC, inner hair cells). (C) RT-PCR was used to verify VGLUT3 mRNA expression in the transfected KO (first lane) and WT (second lane) mice. Rescued whole cochlear extract (R-Co) demonstrates strong VGLUT3 mRNA expression, as does the stria vascularis + organ of Corti lane (R-SV+OC) and vestibular neuroepithelium (R-Vest). Spiral ganglion only shows weak mRNA expression (R-SG). (D and E) Inner hair cells labeled with anti-VGLUT3 antibody after transfection were counted, tabulating both the entire cochlea and within the base, midturn, and apex to determine differences in regions (at P10–P12 delivery, WT n = 5, CO n = 5, RWM n = 6 and at P1–P3 delivery, RWM n = 6). At P10–P12, when 1 μl of virus was microinjected, 100% of IHCs were labeled and similar results were seen at P1–P3 viral delivery (D) when injected with 0.6 μl. In contrast, when 0.6 μl of virus was injected at P10–P12, approximately 40% of IHCs were labeled, with no significant differences seen between the apex, midturn, or base in the variability of IHC labeling with the delivery technique (E). Neuron 2012 75, 283-293DOI: (10.1016/j.neuron.2012.05.019) Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 2 VGLUT3 IHC Transfection: Early versus Late Delivery AAV1-VGLUT3 delivery at P1–P3 versus P10–P12 are compared using similar amount of virus (0.6 μl) and examined at ∼P30. Anti-Myo7a antibody (green) and anti-VGLUT3 antibody (red) are used for staining, and the merged images (yellow) are shown. As expected, IHC from WT mice show both anti-Myo7a and anti-VGLUT3 staining (row 1), whereas KO mice only show anti-Myo7a label (row 2). Delivery of virus via the RWM at P10–P12 results in fewer IHCs expressing VGLUT3 (row 3), whereas similar doses of virus injected at P1–P3 results in 100% of hair cells transfected in all animals (row 4) (IHC, inner hair cells). Neuron 2012 75, 283-293DOI: (10.1016/j.neuron.2012.05.019) Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 3 Hearing Restoration in the VGLUT3 KO Mice (A) Representative ABR and CAP tracings from WT, KO, and rescued KO mice after delivery of 0.6 μl AAV1-VGLUT3. Waveforms from the WT and rescued mice appear similar, while KO mice show no ABR and no CAP responses. “I” indicates the location of ABR wave I. (B) Rescued mice begin to show hearing recovery within 7 days postdelivery (P17–P19), with near normalization of ABR thresholds by 14 days postdelivery (P24–P26). Hearing recovery is seen with both CO and RWM delivery through 69 weeks. Black arrows indicate absence of ABR threshold of the KO above 92 dB (the maximum level that our recording equipment can measure). (C) At 40 days postdelivery (P50–P52), similar levels of recovery are noted at 8 and 16 kHz, while at 32 kHz, CO delivery appears to result in slightly elevated thresholds, though still significantly better than KO. (D) Hearing longevity, as defined as the number of mice with ABR threshold levels within 10 dB of WT levels at each time point, is measured for RWM at P10–P12, CO at P10–P12, and RWM at P1–P3. For viral delivery at P10–P12, CO delivery results in longer-lasting hearing recovery on average than RWM delivery, with some rescued KO in each group maintaining ABR thresholds to within 10 dB of WT animals beyond 28 weeks. However, 100% of rescued KO mice with RWM delivery recover hearing, while only 17% of CO-rescued mice recover hearing. The number of animals with viral delivery at P10–P12 at each time point is the following: RWM 0–9 weeks n = 19, 10–13 weeks n = 12, 14–24 weeks n = 8, 24–28 weeks n = 1, 28+ weeks n = 1; CO 0–7 weeks n = 5, 8–14 weeks n = 4, 15–20 weeks n = 3, 21–28 weeks n = 2, 28+ weeks n = 1. In contrast, in mice undergoing viral delivery at P1–P3, all animals maintain ABR threshold recovery at least through 9 months (n = 5). Neuron 2012 75, 283-293DOI: (10.1016/j.neuron.2012.05.019) Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 4 Behavioral Measures and Physiologic Growth after AAV1-VGLUT3 Rescue (A) Startle responses were studied as an additional behavioral measure of hearing recovery 3 weeks after viral delivery (P31–P33). While none of the rescued mice recover startle responses to WT levels, they nonetheless develop a response, which increases when both ears are rescued; the louder the sound delivered (100, 110, and 120 dB presentation levels), the more robust the startle response was, with rescue of both ears (bilat) creating a larger response than a single ear (unilat). These differences were statistically significant. (B) Similar growth was seen for ABR wave I amplitudes when both ears (bilat) as compared to a single ear (unilat) were rescued, though again not as robust as in the WT mice. (C) ABR wave I latency was measured, which showed no statistically significant differences between unilateral, bilateral, rescued, and WT mice, though there was a trend toward an increased latency in the rescued compared to WT mice. (D) Representative ABR tracings documenting increasing wave I amplitudes from the KO, unilaterally rescued KO (unilat), bilaterally rescued KO (bilat), and WT mice. Neuron 2012 75, 283-293DOI: (10.1016/j.neuron.2012.05.019) Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 5 Spiral Ganglion Cell Counts In these studies, the AAV1-VGLUT3 delivery was done at P10–P12 and at P1–P3. Spiral ganglion (SG) cell counts in rescued mice versus KO and WT mice were undertaken at P21 (A and B) and at 5 months after birth (data not shown) for P10–P12 virus delivery and at two months after birth (data not shown) for P1–P3 virus delivery. AAV1-VGLUT3 transfection did not result in a reversal of the SG neuronal loss in either age group. No significant differences were seen between the groups. These results also document the lack of trauma (C) associated with virally mediated delivery of VGLUT3 through the RWM, with normal organ of Corti morphology, including inner and outer hair cells, spiral ganglion neurons, and stria vascularis (data not shown). Neuron 2012 75, 283-293DOI: (10.1016/j.neuron.2012.05.019) Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 6 Partial Normalization of Synaptic Ribbon Morphology in the Rescued Mice Electron microscopy was performed on broken serial thin sections of the synaptic region of the IHCs, which were cut in a horizontal plane parallel to the basilar membrane in the same orientation for the WT, KO, and rescued KO mice. As previously reported (Seal et al., 2008), VGLUT3 KO mice demonstrate abnormally thin, elongated ribbons in IHC synapses (middle column), as compared to WT littermates (left column). In the rescued mice (right column, single ribbon shown on top, double on the bottom), ribbon synapses are normal appearing, taking on a more rounded shape similar to the WT. Black arrows point to the normal or circular synaptic vesicles and white arrows point to elongated synaptic vesicles. Neuron 2012 75, 283-293DOI: (10.1016/j.neuron.2012.05.019) Copyright © 2012 Elsevier Inc. Terms and Conditions